In the past week, VRTX stock has gone up by 9.44%, with a monthly gain of 18.86% and a quarterly surge of 1.32%. The volatility ratio for the week is 3.39%, and the volatility levels for the last 30 days are 2.51% for Vertex Pharmaceuticals, Inc. The simple moving average for the past 20 days is 11.71% for VRTX’s stock, with a 4.88% simple moving average for the past 200 days.
Is It Worth Investing in Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Right Now?
Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 15 analysts rating it as a “buy,” 4 as “overweight,” 10 as “hold,” and 2 as “sell.”
The public float for VRTX is 256.85M, and currently, short sellers hold a 1.71% ratio of that floaft. The average trading volume of VRTX on February 05, 2025 was 1.64M shares.
VRTX) stock’s latest price update
The stock of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) has increased by 2.53 when compared to last closing price of 470.37.Despite this, the company has seen a gain of 9.44% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-04 that NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated (“Vertex Pharmaceuticals”) (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Wells Fargo repeating the rating for VRTX by listing it as a “Equal Weight.” The predicted price for VRTX in the upcoming period, according to Wells Fargo is $460 based on the research report published on January 30, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $535, previously predicting the price at $600. The rating they have provided for VRTX stocks is “Buy” according to the report published on December 20th, 2024.
VRTX Trading at 9.99% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.23% of loss for the given period.
Volatility was left at 2.51%, however, over the last 30 days, the volatility rate increased by 3.39%, as shares surge +18.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.65% upper at present.
During the last 5 trading sessions, VRTX rose by +9.44%, which changed the moving average for the period of 200-days by +22.69% in comparison to the 20-day moving average, which settled at $431.74. In addition, Vertex Pharmaceuticals, Inc saw 19.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from ALTSHULER DAVID, who sale 15 shares at the price of $478.56 back on Nov 15 ’24. After this action, ALTSHULER DAVID now owns 25,813 shares of Vertex Pharmaceuticals, Inc, valued at $7,178 using the latest closing price.
ALTSHULER DAVID, the Officer of Vertex Pharmaceuticals, Inc, proposed sale 15 shares at $478.56 during a trade that took place back on Nov 15 ’24, which means that ALTSHULER DAVID is holding shares at $7,178 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -2.99, with -2.18 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is 4.61 billion with net debt to EBITDA at -6.83. When we switch over and look at the enterprise to sales, we see a ratio of 11.37. The receivables turnover for the company is 6.06for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.47.
Conclusion
In a nutshell, Vertex Pharmaceuticals, Inc (VRTX) has experienced a better performance in recent times. The stock has received mixed “sell” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
